Dr. Smbat Rafayelyan

Founder & CEO at Bioneex

📍 Germany🔄 Updated September 2026💼 2 investments📅 7 years investing🗓 Last invested Jun 2023
Operator-angel🌍 Germany
2
Total investments
1
Early stage
0
Mid stage
0
Late stage
7y
Years active

Portfolio

1 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Investor
Jun 2023
At Addimmune, our mission is to deliver the world’s first functional cure for HIV. Using viral vector delivery, we are seeking to give the immune system the tools it needs to resist and ultimately clear the virus.
Experience · 5 entries
All (5)
Investments (2)
Founder (1)
2023
Investor
Jun 2023
At Addimmune, our mission is to deliver the world’s first functional cure for HIV. Using viral vector delivery, we are seeking to give the immune system the tools it needs to resist and ultimately clear the virus.
2019
Investor
Dec 2019
American Gene Technologies® International Inc. (AGT™) is a private biotechnology company pursuing cures and treatments for infectious diseases, cancers, and monogenic disorders. AGT™s emerging gene and cell therapeutics programs are designed to: ✅ Create immunotherapy for HIV disease with gene-modified T cells ✅ Activate innate T cell immunity capable of killing all tumor cells with its vector used in immuno-oncology ✅ Treat PKU by bringing a functional gene into cells that express a dysfunctional gene due to mutation ✅ Advance clinically to provide human proof of concept For over a decade, AGT™ has developed, tested, and banked thousands of lentiviral vectors that can be adapted to the specific needs of new target diseases. AGT™ has developed gene therapy for diseases using this rapid gene delivery platform. GENE THERAPIES AGT™’s platform allows it to pursue clinical “cures” for complex diseases. The company has developed patent-protected gene therapeutics that are breakthroughs in medicine. *** See our extensive award winning patents on our website *** HIV/AIDS Immunotherapy for HIV disease with gene-modified T cells IMMUNO-ONCOLOGY Activates innate T cell immunity capable of killing all tumor cells with its vector used in immuno-oncology PHENYLKETONURIA (PKU) Treats PKU by bringing a functional gene into cells that express a dysfunctional gene due to mutation AGT™s Core Objectives ✔️ Leverage our lentivirus platform to create highly-effective targeted genetic medicines ✔️ Create solutions for patients across a spectrum of infectious diseases, cancers and inherited disorders ✔️ Collaborate with leading medical researchers from around the globe To learn more and get in touch with American Gene Technologies® Inc., contact us today at https://www.americangene.com/contact-us/
2018
Founder & CEO
Jan 2018
Bioneex is the first AI-powered drug candidates marketplace. It connects drug development companies with biopharma partners and venture capital investors to facilitate licensing, co-development partnership deals for preclinical and clinical-stage drug candidates, and investments. On one side, the platform enables innovative drug development companies to list their novel drug candidates and directly contact hundreds of biopharma partners and venture capital investors actively seeking development-stage assets (preclinical to phase III) for in-licensing, co-development partnership, and investment. On the other side, the platform enables biopharma companies and venture capital firms to identify and access novel development-stage assets (preclinical to phase III) posted directly by drug development companies and directly contact them with one click. In essence, Bioneex provides a platform for drug development companies, biopharma partners and venture capital investors, where they can meet and create R&D partnerships and investment deals. Bioneexs vision is helping preclinical and clinical-stage drug development companies gain for their medicines in development vital exposure to the right partners and investors at the right time, which will increase the likelihood of moving these innovative drug candidates into the next stage of development and, ultimately to the patients as novel medicines.
2014
Pharmaceutical Associate
Oct 2014
We’re celebrating over 175 years of daring scientific innovation—and we’re not done yet. Let’s outdo yesterday. Protect your health at PfizerForAll.com For additional information on our guidelines, please visit http://www.pfizer.com/community-guidelines
2010
Scientific Associate in Oncology
Oct 2010
We are an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Interactions with this account must comply with the Terms: https://bit.ly/sanofi-terms